IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines

Pancreas

Volumn 41, Issue 5, 2012, Pages 773-781

  Block, Katherine M ^a   Hanke, Neale T ^a   Maine, Erin A ^a   Baker, Amanda F ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Interleukin 6; Pancreatic cancer; Pim 1 kinase; Signal transducer and activator of transcription 3

Indexed keywords

CUCURBITACIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE PIM 1; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-PIM-1; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES; TUMOR BURDEN;

EID: 84863686744     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823cdd10     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CACancer J Clin. 2010;60:277-300.
2. Tabata T, Fujimori T, Maeda S, et al. The role of Ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int J Pancreatol. 1993;14:237-244.
3. Ancrile B, Lim KH, Counter CM. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007;21:1714-1719.
4. Ancrile BB, O'Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interv. 2008;8:22-27.
5. Masui T, Hosotani R, Doi R, et al. Expression of IL-6 receptor in pancreatic cancer: involvement in VEGF induction. Anticancer Res. 2002;22:4093-4100.
6. Adam N, Rabe B, Suthaus J, et al. Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol. 2009;83:5117-5126.
7. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296:1653-1655.
8. Scheller J, Ohnesorge N, Rose-John S. Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol. 2006;63:321-329.
9. Huang C, Yang G, Jiang T, et al. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010;29:51.
10. Toyonaga T, Nakano K, Nagano M, et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett. 2003;201:107-116.
11. Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005;37:726-730.
12. Qian J, Niu J, Li M, et al. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res. 2005;65:5045-5053.
13. Shah N, Pang B, Yeoh KG, et al. Potential roles for the PIM1 kinase in human cancer-a molecular and therapeutic appraisal. Eur J Cancer. 2008;44:2144-2151.
14. Bullock AN, Debreczeni J, Amos AL, et al. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem. 2005;280:41675-41682.
15. Mochizuki T, Kitanaka C, Noguchi K, et al. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem. 1999;274:18659-18666.
16. Bachmann M, Kosan C, Xing PX, et al. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol. 2006;38:430-443.
17. Zippo A, De RA, Serafini R, et al. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol. 2007;9:932-944.
18. Zhang Y, Wang Z, Li X, et al. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008;27:4809-4819.
19. Peng C, Knebel A, Morrice NA, et al. Pim kinase substrate identification and specificity. J Biochem. 2007;141:353-362.
20. Chen J, Kobayashi M, Darmanin S, et al. Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene. 2009;28:2581-2592.
21. Zemskova M, Sahakian E, Bashkirova S, et al. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008;283:20635-20644.
22. Ignatoski KM, Friedman J, Escara-Wilke J, et al. Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. J Interferon Cytokine Res. 2009;29:105-112.
23. Feurino LW, Zhang Y, Bharadwaj U, et al. IL-6 stimulates Th2 type cytokine secretion and upregulates VEGF and NRP-1 expression in pancreatic cancer cells. Cancer Biol Ther. 2007;6:1096-1100.
24. Lui VW, Yau DM, Wong EY, et al. Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis. 2009;30:2085-2094.
25. Ishdorj G, Johnston JB, Gibson SB. Cucurbitacin I (JSI-124) activates the JNK/c-jun signaling pathway independent of apoptosis and cell cycle arrest in B Leukemic Cells. BMC Cancer. 2011;11:268.
26. Reiser-Erkan C, Erkan M, Pan Z, et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther. 2008;7:1352-1359.
27. Adachi Y, Aoki C, Yoshio-Hoshino N, et al. Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer. 2006;119:1303-1311.
28. Aksoy I, Sakabedoyan C, Bourillot PY, et al. Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3. Stem Cells. 2007;25:2996-3004.
29. Willert M, Augstein A, Poitz DM, et al. Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation. Basic Res Cardiol. 2010;105:267-277.
30. Blaskovich MA, Sun J, Cantor A, et al. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003;63:1270-1279.
31. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8:241-252.
32. Krumenacker JS, Narang VS, Buckley DJ, et al. Prolactin signaling to pim-1 expression: a role for phosphatidylinositol 3-kinase. J Neuroimmunol. 2001;113:249-259.
33. Andreucci M, Lucisano G, Faga T, et al. Differential activation of signaling pathways involved in cell death, survival and inflammation by radiocontrast media in human renal proximal tubular cells. Toxicol Sci. 2011;119:408-416.
34. Xu D, Allsop SA, Witherspoon SM, et al. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis. 2011;32:488-495.
35. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14:109-119.